In part 8, we discussed the internal capability side of CGT commercialization: the elevated expertise required of field-facing teams and the cross-functional coordination needed to keep the external experience coherent. Those capabilities do not just appear at launch. They are the product of commercial planning and decision-making that begins years earlier, which is the subject of this article. What many CGT manufacturers still underestimate is how much of a launch’s trajectory is set before launch (and how narrow the window for course correction becomes once it is underway if the means to course-correct were not built in advance).

Start Commercial Planning Two to Three Years Before Launch

Commercial planning for CGTs cannot begin at a Phase III readout. By that point, too many of the decisions that will constrain a launch have already been made by default. The realistic window to begin serious commercial planning is 2-3 years pre-launch, and even earlier for products with particularly complex logistics or novel disease-area dynamics. Planning builds on the medical and scientific groundwork already underway as well as what we call the Patient-Product-Access Journey, which details each step from symptom presentation to treatment follow-up, including where leakage occurs and how much. This view is a key foundational element for commercial planning: it is what turns observed leakage into specific mitigation strategies and tactics.

What needs to happen in this window is substantial. Early market research shapes the understanding of stakeholder needs across referring physicians, authorized treatment centers (ATCs), payers, and patients. In turn, that understanding shapes downstream investment in everything from patient support design to field team structure to evidence generation priorities. Site network planning, hub design, data and analytics infrastructure, and hiring for specialized roles all have lead times measured in quarters, not weeks. Payer engagement, as discussed in earlier parts of this series, benefits from years of relationship-building rather than a pre-launch sprint. Early work is deliberately staged: market research, journey mapping, and site network analysis hold value across indications, while hub build-out, hiring, and system implementation are gated on emerging clinical signals.

The manufacturers that treat this pre-launch period as scaffolding for the launch itself, rather than as preparation for a discrete launch event, are the ones whose commercial machinery is actually running when the first patients enroll. Those that don’t will typically discover the cost in the first few months, when the infrastructure they needed on day one is still being built.

Build for Real-Time Course Correction, Not Quarterly Reporting

Traditional launch dashboards were built to track prescription volume, market share, and channel performance in near-monthly cycles. CGT launches don’t work that way. Patient populations are small (although traction towards broader population CGT is building), so a single stalled patient is a material share of launch performance. In addition, the logistics are complex enough that small operational issues become material quickly, and the funnel from initial referral to infusion contains many stages where attrition can happen. A quarterly view of what is happening is far too slow to inform useful action. Value chain visibility is most critical in the months right after launch, when trends are still forming and early funnel signals are the earliest credible leading indicators of launch success. Pivots are common in that period, and they depend on seeing where the real-world value chain is straining.

The best-designed infrastructure will surface near-real-time signals across the parts of the funnel that determine outcomes:

  • Eligible patients actually recognized as eligible, and the share that converts to a referral
  • Referral volume and conversion by community site and ATC
  • Time from referral to enrollment, enrollment to apheresis (where relevant), and apheresis to infusion
  • Drop-off points along the funnel and the reasons behind them
  • ATC-level throughput and any early signs of operational strain at specific centers
  • Coverage and reimbursement outcomes by payer and plan type

ATC-level throughput does double duty: beyond flagging operational strain, it shows how efficiently care is delivered at each site and where variability across sites needs attention.

Importantly, measurement that begins at referral does not capture patients who are never recognized as eligible, and a drop-off figure that mixes addressable leakage with appropriate clinical exclusion sends teams to solve the wrong problem. Latency matters for a different reason: patients progress while the process runs, so time-to-treat is itself a driver of attrition. That is what makes a monthly reporting cadence too slow and unreliable.

None of these signals appear on their own. Data-sharing agreements with ATCs, feeds from the hub and specialty distributors, and the integration work to connect them have lead times measured in quarters, which is why they belong in the pre-launch plan rather than the first-year fix list.

Just as critical as the data itself is the operating cadence around it. Cross-functional reviews held weekly or every two weeks, with clear ownership for action—rather than monthly readouts to leadership—are what allow teams to intervene while intervention can still make a difference. It is much easier to catch a slowing referral trend or a struggling ATC in week two than to unwind six weeks of accumulated drift.

Design the Go-to-Market Model for a One-Time Market

The third foundational shift is the hardest for organizations built around chronic therapies to absorb. A one-time treatment changes almost every commercial parameter.

Field team sizing is the most visible example. A product that treats a small, geographically concentrated population once does not need the field footprint of a chronic specialty product, and over-sizing leads to unproductive activity and diluted expertise. Under-sizing produces its own problems in a market where every stakeholder relationship matters. The right answer depends on disease and channel dynamics, but it is almost never a scaled-down version of a chronic playbook.

Incentive structures require similar rethinking. Compensation built around prescription volume makes little sense for a therapy with no repeat prescribing. Effective CGT incentive models reward the activities that actually move the funnel: ATC readiness and productivity, referral generation and quality, patient journey completion, and cross-functional contribution to complex accounts. These metrics are harder to measure than scripts, but they are essential to getting the full picture.

Forecasting is the third area reshaped by one-time economics. Eligible populations decline as treated patients accumulate, a dynamic most commercial forecasting tools are not built for. Credible forecasts account for prevalent-versus-incident mix, penetration curves that flatten as the prevalent pool is worked through, and new indications or geographies that reopen eligible populations. They also reconcile against capacity, which chronic models rarely need to do: demand that cannot be slotted is not revenue, and a missed slot is not a deferred sale but a patient who may progress out of eligibility. Manufacturers that stick with chronic-style forecasting tend to over-project years two and three, and the corrections that follow are painful.

The Bottom Line

Commercial foundation and infrastructure are not the flashy part of CGT commercialization, but they largely determine launch success. Manufacturers that start planning 2-3+ years out, build the infrastructure to see and respond to the funnel in near-real time, and design their go-to-market model around one-time economics run launches that are organized, adaptive, and credible. Those that compress the planning window, rely on traditional launch analytics, and default to chronic-market playbooks spend the first year in reactive mode, fixing what could have been designed properly from the start.

Next in the series: Success Factor 10 – External Communications.